Prev：Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response.(KTE6014-10.3)
Next：Role of baseline soluble tumor necrosis factor receptor 2 as a biomarker in primary podocytopathy: Implications for renal impairment and disease progression.(KTE6032-2.2)
